Medpace Holdings (MEDP) Earnings Date & Reports
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms... Show more
MEDP is expected to report earnings to fall 7.01% to $3.98 per share on July 27
Medpace Holdings, Inc. (MEDP) Q1 2026 Earnings Recap: Revenue Beats as Bookings Pressure Shares
Key Takeaways
- Revenue climbed 26.5% year-over-year to $706.6 million, surpassing consensus estimates of approximately $697 million.
- GAAP diluted earnings per share (EPS) reached $4.28, up 16.6% from $3.67 in Q1 2025 and beating analyst expectations around $3.90.
- Net new business awards totaled $618.4 million, yielding a net book-to-bill ratio (awards divided by revenue) of 0.88x, below the 1.0x threshold investors favor for growth visibility.
- Full-year 2026 guidance calls for revenue of $2.755 billion to $2.855 billion and GAAP diluted EPS of $16.68 to $17.50.
- Shares plunged nearly 20% in after-hours trading following the release, driven by the bookings shortfall and a leadership transition announcement.
Earnings Context and Why It Matters
Medpace Holdings, Inc. (MEDP), a leading full-service contract research organization (CRO), provides clinical development services to biotech, pharma, and medtech firms. This Q1 2026 report is pivotal as it reflects recovering demand post-biotech funding droughts, with revenue surging on prior backlog conversion. However, scrutiny falls on net new awards and book-to-bill ratio, key indicators of future pipeline strength amid volatile trial starts. Prior quarters showed booking fluctuations, influencing stock volatility. For investors, these results signal operational resilience but highlight risks in award wins, guiding assessments of sustained growth in a competitive CRO landscape.
Medpace reported Q1 2026 revenue of $706.6 million, a 26.5% increase from $558.6 million in the year-ago quarter, driven by a 23.3% backlog conversion rate. This topped consensus estimates near $697 million. GAAP net income rose 8.1% to $123.9 million, with diluted EPS of $4.28 exceeding forecasts of about $3.90 and up from $3.67 prior year. EBITDA grew 25.9% to $149.4 million (21.1% margin).
Net new business awards increased 23.7% to $618.4 million from $500.0 million, but the book-to-bill ratio slipped to 0.88x. Backlog expanded 2.9% to $2.93 billion. Operating cash flow strengthened to $151.8 million, bolstering a cash position of $652.7 million. The company repurchased $371.9 million in shares during the quarter.
Full-year 2026 guidance projects revenue growth of 8.9% to 12.8% to $2.755-$2.855 billion (from $2.53 billion in 2025), GAAP net income of $487-$511 million, and diluted EPS of $16.68-$17.50. EBITDA is expected at $605-$635 million.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research workflow.
Market Reaction and Investor Sentiment
Despite topping revenue and EPS estimates, MEDP shares tumbled about 20% in after-hours trading on April 22, 2026. The selloff stemmed from the sub-1.0x book-to-bill ratio signaling potential pipeline softening, full-year guidance viewed as modest relative to Q1 momentum, and news of President Jesse Geiger's retirement effective May 31, 2026. CEO August Troendle will assume the role interim. Sentiment turned cautious, with focus shifting to award recovery.
Forward Outlook and Key Factors to Monitor
Medpace's FY2026 guidance implies more measured growth after Q1's robust start, with revenue expansion of 8.9%-12.8%. Investors should track quarterly net new awards to assess if book-to-bill rebounds above 1.0x, bolstering backlog growth beyond the current $2.93 billion.
The leadership transition, with CEO Troendle temporarily leading as President, warrants watching for continuity in client relationships and strategic execution. No disruptions are anticipated, but succession updates will be key.
Operational metrics like backlog conversion (23.3% in Q1), EBITDA margins (21.1%), and cash generation ($151.8 million operating cash flow) remain strengths. Share repurchases continue, with $372 million executed in Q1. Broader CRO demand, influenced by biotech funding and trial initiations in oncology and rare diseases, plus cost discipline amid reimbursable expenses, will shape trajectory. Upcoming Q2 results in July will provide clarity on awards momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a holding company
Industry MedicalSpecialties